Shares of Cytori Therapeutics Inc (NASDAQ:CYTX) dropped 7.9% on Monday . The stock traded as low as $0.34 and last traded at $0.35. Approximately 1,921,600 shares were traded during mid-day trading, a decline of 44% from the average daily volume of 3,448,922 shares. The stock had previously closed at $0.38.

CYTX has been the topic of several analyst reports. Maxim Group set a $5.00 target price on shares of Cytori Therapeutics and gave the company a “buy” rating in a report on Monday, November 13th. Zacks Investment Research raised shares of Cytori Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, January 2nd. Finally, B. Riley reaffirmed a “hold” rating on shares of Cytori Therapeutics in a report on Tuesday, November 7th.

The company has a market cap of $12.99, a price-to-earnings ratio of -0.41 and a beta of 3.21.

Cytori Therapeutics (NASDAQ:CYTX) last issued its earnings results on Thursday, November 9th. The biotechnology company reported ($0.14) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.16) by $0.02. The firm had revenue of $1.77 million for the quarter, compared to analysts’ expectations of $2.04 million. Cytori Therapeutics had a negative net margin of 367.33% and a negative return on equity of 228.21%. During the same quarter last year, the company earned ($0.26) earnings per share. analysts predict that Cytori Therapeutics Inc will post -0.62 earnings per share for the current fiscal year.

In related news, major shareholder Bank Sa Swissquote sold 100,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 9th. The shares were sold at an average price of $0.38, for a total value of $38,000.00. Following the sale, the insider now owns 5,496,655 shares of the company’s stock, valued at $2,088,728.90. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 1.90% of the stock is owned by company insiders.

A hedge fund recently raised its stake in Cytori Therapeutics stock. Vanguard Group Inc. grew its stake in shares of Cytori Therapeutics Inc (NASDAQ:CYTX) by 81.9% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 612,304 shares of the biotechnology company’s stock after purchasing an additional 275,653 shares during the quarter. Vanguard Group Inc. owned approximately 1.89% of Cytori Therapeutics worth $674,000 as of its most recent filing with the Securities and Exchange Commission. 7.41% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This piece of content was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The correct version of this piece of content can be read at https://www.thecerbatgem.com/2018/01/17/cytori-therapeutics-cytx-trading-down-7-9.html.

About Cytori Therapeutics

Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.

Receive News & Stock Ratings for Cytori Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics and related stocks with our FREE daily email newsletter.